Sonoma Pharmaceuticals Inc. (NASDAQ:SNOA) rose 16.40% in after-hours trading to $2.44 on Thursday. The surge in the late trading session followed a 7.89% decline during the regular session.Retail Expansion Drives After-Hours JumpAccording to Sonoma, the over-the-counter product targets minor burns and skin irritations, marking SNOA’s first large-scale consumer burn relief offering. Distribution runs through an unnamed U.S.-based partner that supplies CVS and Walmart.CEO Cites Growing Consumer Awareness“This ...

Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart ELEMENT-- Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart BOULDER, CO / ACCESS Newswire/ March 24, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader in hypochlorous acid (HOCl) technology, today announced the U.S. retail launch of its advanced HOCl-based burn relief hydrogel in CVS and Walmart stores nationwide. The hydrog ...

Core Insights - Sonoma Pharmaceuticals, Inc. reported a revenue increase of 22% for the quarter ended December 31, 2025, and 33% for the nine months ended December 31, 2025, compared to the prior year [1] - The company experienced a decrease in net loss and net loss per share for both the three months and nine months ended December 31, 2025, compared to the prior year [1] - EBITDAS loss decreased by $0.4 million and $0.9 million for the three and nine months ended December 31, 2025, respectively, compared to the prior year [1] Company Overview - Sonoma Pharmaceuticals is a global healthcare leader focused on developing and producing stabilized hypochlorous acid (HOCl) products for various applications, including wound care, eye care, dermatological conditions, podiatry, animal health care, and non-toxic disinfectants [1] - The CEO of Sonoma Pharmaceuticals, Amy Trombly, expressed satisfaction with the continued revenue growth, indicating effective execution of the company's strategic priorities [1]

Revenue Performance - Total revenue for the three months ended December 31, 2025, was $4,349,000, representing a 22% increase from $3,564,000 in the same period of 2024[86] - Revenue in the United States increased by 98% to $1,218,000, primarily due to higher sales of over-the-counter products and increased sales by new and existing distributors[87] - Revenue in Europe rose by 24% to $1,560,000, driven by increased demand for products[88] - Revenue in Asia increased by 38% to $800,000, while revenue from the Rest of the World decreased by 11% to $253,000[86] - Revenue in Latin America decreased by 38% to $518,000, primarily due to the timing of customer orders for overflow manufacturing[89] - Total revenue for the nine months ended December 31, 2025 was $13,968,000, an increase of $3,434,000 (33%) compared to the prior year, with U.S. revenue up 90%[97] Product Development and Innovation - The company has developed unique dermatologic products targeting conditions such as redness, irritation, and eczema, with a focus on innovative new products supported by clinical data[66] - In January 2024, the company launched Lumacyn Clarifying Mist, an all-natural daily toner for skin care, expanding its product line in the U.S.[68] - A Master Supply Agreement was entered into with WellSpring Pharmaceutical Corporation for the sale of Microcyn technology-based products to large retailers in the U.S., with an initial term of two years[69] - The company announced a new application of HOCl technology for intraoperative pulse lavage irrigation treatment, launched in the U.S. in November 2023[74] - The Microcyn Negative Pressure Wound Therapy Solution product line was expanded in April 2024, now available in sizes of 250mL, 450mL, and 990mL[75] Financial Performance - For the three months ended December 31, 2025, gross profit increased by $380,000 (30%) to $1,650,000, driven by higher revenue and product mix improvements[90] - Gross profit for the nine months ended December 31, 2025 increased by $1,297,000 (33%) to $5,234,000, attributed to revenue growth and product mix[100] - Research and development expenses for the three months ended December 31, 2025 rose by $130,000 (30%) to $557,000, primarily due to increased product development for new releases[91] - Research and development expenses for the nine months ended December 31, 2025 increased by $323,000 (23%) to $1,726,000, supporting new product development[101] - Selling, general and administrative expenses decreased by $103,000 (5%) to $1,771,000, reflecting ongoing cost control efforts[93] - Net loss for the nine months ended December 31, 2025 was $2,594,000, compared to a net loss of $2,681,000 in the prior year[106] - Cash and cash equivalents at the end of the period were $2,561,000, down from $5,374,000 at the beginning of the period[111] - Net cash used in operating activities for the nine months ended December 31, 2025 was $3,414,000, primarily due to the net loss and increases in inventory and prepaid expenses[112] - The company reported an accumulated deficit of $200,400,000 as of December 31, 2025, indicating ongoing financial challenges[107] Risk Factors - The company is exposed to risks from foreign currency devaluation, particularly with the Mexico Peso and Euro against the US dollar[118] - There is a substantial Mexico tax liability and intercompany debt due in 2027, but management believes there are sufficient assets to cover these obligations[119] - The company is monitoring global economic conditions, including risks of economic downturns and consumer sentiment, which may impact financial results[120] - The One Big Beautiful Bill Act ("OBBBA") enacted in July 2025 is expected to have an insignificant impact on deferred tax assets and liabilities[121] - Management makes estimates and assumptions that affect reported amounts of assets and liabilities, which could differ from actual results[122] - There are currently no off-balance sheet arrangements that could materially affect the company's financial condition[123] - As a smaller reporting company, the company is electing scaled disclosure reporting obligations and is not required to provide certain market risk information[124]

Core Viewpoint - Sonoma Pharmaceuticals, Inc. has appointed Vanessa Jacoby to its Board of Directors and as Chair of its Audit Committee, while announcing the retirement of Dr. Jay Birnbaum [1] Group 1: Company Developments - Vanessa Jacoby, previously Chief Business and Financial Officer of Quanta Therapeutics, Inc., joins Sonoma Pharmaceuticals' Board of Directors [1] - The company has announced the retirement of longtime director Dr. Jay Birnbaum [1] Group 2: Product and Technology - Sonoma Pharmaceuticals specializes in developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for various applications [1] - The applications of Sonoma's products include wound care, eye care, dermatological conditions, podiatry, and animal health care [1]

Core Viewpoint - Sonoma Pharmaceuticals, Inc. is set to showcase its patented Microcyn® technology-based products at MEDICA 2025, highlighting its leadership in the healthcare sector [1] Company Summary - Sonoma Pharmaceuticals specializes in developing and producing stabilized hypochlorous acid (HOCl) products for various applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care [1] Industry Summary - MEDICA 2025 is one of the largest and most prestigious medical B2B trade fairs globally, expected to attract 80,000 visitors from 72 countries and over 5,000 exhibitors [1]

Revenue Performance - Total revenue for the three months ended September 30, 2025, was $5,604,000, representing a 57% increase from $3,579,000 in the same period of 2024[85] - Revenue from the United States increased by $774,000 (115%) due to higher sales of human health care and over-the-counter animal health care products[85] - European revenue rose by $645,000 (43%) driven by a general increase in demand for products[86] - Revenue from Asia increased by $281,000 (36%) primarily due to the timing of orders, with fluctuations expected from international distributors[86] - Latin America revenue grew by $67,000 (14%) attributed to the timing of customer orders for overflow manufacturing[87] - Rest of the World revenue surged by $258,000 (164%) also due to the timing of customer orders[87] - Total revenue for the six months ended September 30, 2025 was $9,619,000, an increase of $2,649,000 (38%) compared to $6,970,000 in 2024[96] - The United States revenue for the six months ended September 30, 2025 increased by $1,137,000 (86%) to $2,454,000, mainly due to human health care products[96] Profitability - For the three months ended September 30, 2025, gross profit increased by $759,000 (56%) to $2,120,000, driven by higher revenue and product mix[88] - Gross profit for the six months ended September 30, 2025 was $3,584,000, up by $917,000 (34%) from $2,667,000 in 2024[99] - The net loss for the three months ended September 30, 2025 was $534,000, an improvement from a net loss of $610,000 in the same period of 2024[94] - The company reported a net loss of $1,775,000 for the six months ended September 30, 2025, compared to a net loss of $1,753,000 in 2024[104] Expenses - Research and development expenses for the three months ended September 30, 2025 rose by $69,000 (14%) to $575,000, primarily due to increased product development[89] - Selling, general and administrative expenses increased by $177,000 (10%) to $1,882,000 for the three months ended September 30, 2025, reflecting efforts to boost revenues across regions[91] Cash Flow and Financial Position - Cash and cash equivalents at the end of the period were $3,035,000, down from $5,374,000 at the beginning of the period[108] - Net cash used in operating activities for the six months ended September 30, 2025 was $2,650,000, primarily due to the net loss and increases in accounts receivable and inventory[110] Risks and Liabilities - The company relies on a small number of key customers for a significant portion of its revenues, which may lead to revenue fluctuations in future periods[114] - The company is exposed to foreign currency devaluation risks, particularly with the Mexico Peso and Euro against the US dollar, which can be unpredictable[115] - A substantial Mexico tax liability, intercompany debt, and accrued interest are due in 2027, but management believes there are sufficient assets to cover these obligations[116] - The company is closely monitoring global economic conditions, including risks of economic downturns and changes in consumer sentiment that may impact financial results[117] Regulatory and Reporting Matters - The One Big Beautiful Bill Act ("OBBBA") enacted on July 4, 2025, is expected to have an insignificant impact on deferred tax assets and liabilities and income taxes payable[118] - The preparation of financial statements involves estimates and assumptions that could differ from actual results, particularly regarding deferred tax assets[119] - There are currently no off-balance sheet arrangements that materially affect the company's financial condition or results of operations[120] - As a smaller reporting company, the company is electing scaled disclosure reporting obligations and is not required to provide certain market risk information[121] Product Development and Agreements - The company has developed a new application of HOCl technology for intraoperative pulse lavage irrigation treatment, launched in the U.S. in November 2023[73] - A Master Supply Agreement was established with WellSpring Pharmaceutical Corporation for the sale of Microcyn technology-based products to large retailers in the U.S. for an initial term of two years[68] - The company relaunched several dermatology products in December 2024, including Epicyn Facial Cleanser and Levicyn Antimicrobial Dermal Spray[66] - The Microcyn Negative Pressure Wound Therapy Solution product line was expanded in April 2024 to include sizes of 250mL, 450mL, and 990mL[74]

Group 1 - The article does not provide any specific content related to a company or industry [1]

Core Insights - Sonoma Pharmaceuticals, Inc. has successfully registered its manufacturing facility and listed its Microcyn-based facial spray under the FDA's Modernization of Cosmetics Regulation Act of 2022 (MoCRA) [1] - This registration allows Sonoma to expand its regulatory footprint, enabling the company to manufacture and commercialize Microcyn technology products as cosmetics in the United States [1] Company Developments - The registration under MoCRA signifies a strategic move for Sonoma Pharmaceuticals to enhance its product offerings in the cosmetics market [1] - The Microcyn technology-based products are positioned to leverage the growing demand for innovative cosmetic solutions [1]

Core Viewpoint - Sonoma Pharmaceuticals, Inc. is participating in the Lytham Partners Fall 2025 Investor Conference, indicating its ongoing engagement with investors and the market [1] Company Participation - The company will host a webcast presentation on September 30, 2025, at 2:00 p.m., showcasing its patented Microcyn® technology and its applications [1] - Sonoma Pharmaceuticals will also conduct one-on-one meetings with investors during the conference, highlighting its commitment to investor relations [1] Product Focus - The company specializes in developing and producing stabilized hypochlorous acid (HOCl) products for various applications, including wound care, eye care, dermatological conditions, podiatry, and animal health care [1]